Dr. Blackburn has been President of Mercia since it was founded in 2002. Prior to Mercia, he served as VP of Programs for Aphton Corporation and in 1985, Dr. Blackburn helped found Applied Microbiology, Inc. (NASDAQ:AMBI) as Research Director eventually serving as Chief Executive and member of the Board of Directors. Dr. Blackburn has over 25 years experience in biologics drug development and is the inventor on over 20 US patents and patent applications. Dr. Blackburn received his Ph.D. in Biochemistry from Sheffield University, UK, and his post-doctoral training in Protein Chemistry with Professors Stanford Moore and William H. Stein at Rockefeller University, NY. Prior to joining industry was Assistant Professor Biochemistry Rockefeller University, NY, and Associate Professor Public Health Research Institute, NY.
Dr. White is a founder of Mercia and the founder and Chairman of Nova Laboratories Limited, a privately held contract manufacturing company in the U.K. Dr. White has over 30 years pharmaceutical GMP-compliant manufacturing experience including development and scale-up of sophisticated aseptic processing techniques. Dr. White is responsible for GMP manufacture of all of Mercia’s products from pilot production through scale-up. Dr. White has a Ph.D. in Pharmaceutical Technology from DeMontfort University in the UK.
Dr. Michaeli served as Chief Medical Officer for Aphton Corp. from 1990 until 2005. Prior to joining industry, Dr. Michaeli was a Professor of Medicine at UCSF. Dr. Michaeli has been responsible for the planning and direction of more than 20 clinical trials with antigen-specific immunotherapeutic products conducted in the US, UK and EU. Dr. Michaeli received his Ph.D. in Biochemistry from the Univ of CA, Berkley and his M.D. from UCSF.